266 |
Optimal Antithrombotics After TAVR |
Duk-Woo Park |
Aug. 08. 19 |
265 |
Who Should Not Undergo TAVR? Key Insights from the Pivotal Trials and Registries |
David Joel Cohen |
Aug. 08. 19 |
264 |
The Optimal Antithrombotic Strategy in Patients with AF and ACS: Focusing on the AUGUSTUS Trial |
Kyung Woo Park |
Aug. 08. 19 |
263 |
Clinical Challenges in CKD Patients with AF: Renal Safety of Rivaroxaban |
Hong Euy Lim |
Aug. 08. 19 |
262 |
Is LAA Closure a Valid Alternative? No, NOACs Are Strongly Preferred to LAA Closure! |
Tae-Hoon Kim |
Aug. 08. 19 |
261 |
Post LAAO Anti-thrombotic Regimens and for How Long After the Closure |
Anthony Yiu Tung Wong |
Aug. 08. 19 |
260 |
Choosing the Right Device for the Right Anatomy |
Cheung Chi Simon Lam |
Aug. 08. 19 |
259 |
Minimalist TAVR: AMC Experience |
Seung-Jung Park |
Aug. 08. 19 |
258 |
Coronary Access After TAVR |
Edgar Lik-Wui Tay |
Aug. 08. 19 |
257 |
Current Status of TAVR in Korea and US: TP-TAVR Registry |
Duk-Woo Park |
Aug. 08. 19 |